Malwina Rybicka-Ramos1, Miroslaw Markiewicz2, Aleksandra Suszka-Switek3, Ryszard Wiaderkiewicz3, Sylwia Mizia4, Monika Dzierzak-Mietla5, Krzysztof Bialas6. 1. Specialist Hospital No. 1 in Bytom, Department of Hematology Bytom, Poland. 2. University of Rzeszow, College of Medical Sciences, Institute of Medical Sciences, Department of Hematology Rzeszow, Poland. 3. School of Medicine in Katowice, Medical University of Silesia, Department of Histology and Embryology Katowice, Poland. 4. Faculty of Health Science, Wroclaw Medical University, Department of Public Health, Department of Organization and Management Wroclaw, Poland. 5. Maria Sklodowska-Curie National Research Institute of Oncology, Department of Bone Marrow Transplantation and Hematooncology Gliwice, Poland. 6. SPSK-M Hospital, Department of Hematology and Bone Marrow Transplantation Katowice, Poland.
Abstract
OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with a risk of graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is related to T-lymphocytes, which identify alloantigens on host antigen-presenting cells, induce production of interferon (IFN) gamma and interleukin (IL)-2, recruit immune effector cells and destroy tissues and organs. MATERIAL AND METHODS: The study involved 62 patients, 30 (48%) men and 32 (52%) women [median age 49.5; (19-68) years] after myeloablative conditioning (MAC) n = 26 (42%) or reduced intensity conditioning (RIC) n = 36 (58%) therapy before allo-HSCT from a sibling (n = 12) or unrelated (n = 50) donor due to acute myeloid leukemia (AML). All patients received standard immunosuppressive therapy with cyclosporine A and methotrexate plus pre-transplant anti-thymocyte globulin in the unrelated transplant setting. Blood samples were collected pre-transplant before the start of and after conditioning therapy (1 day pre-transplant) and 2, 4, 6, 10, 20, 30 days following allo-HSCT. The analysis of potential risk factors included IL-2 and IFN-gamma concentrations, patients' age, the use of MAC/RIC and CR/non-CR status before transplantation. RESULTS: The statistical analysis revealed that independent risk factors for aGvHD included non-CR status before allo-HSCT [odds ratio (OR) = 10.52, P = 0.040], the use of MAC [hazard ratio (HR) = 4.80, P = 0.007] and a high level of IFN-gamma on day 6 post-transplant (HR = 1.03, P = 0.032). MAC was also the independent risk factor for infectious complications (OR = 4.04, P = 0.024). CONCLUSION: A high level of IFN-gamma on day 6 post-transplant, non-CR status before allo-HSCT and the use of MAC are independent risk factors for aGvHD. MAC is also the independent risk factor of infectious complications. AJBR
OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with a risk of graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is related to T-lymphocytes, which identify alloantigens on host antigen-presenting cells, induce production of interferon (IFN) gamma and interleukin (IL)-2, recruit immune effector cells and destroy tissues and organs. MATERIAL AND METHODS: The study involved 62 patients, 30 (48%) men and 32 (52%) women [median age 49.5; (19-68) years] after myeloablative conditioning (MAC) n = 26 (42%) or reduced intensity conditioning (RIC) n = 36 (58%) therapy before allo-HSCT from a sibling (n = 12) or unrelated (n = 50) donor due to acute myeloid leukemia (AML). All patients received standard immunosuppressive therapy with cyclosporine A and methotrexate plus pre-transplant anti-thymocyte globulin in the unrelated transplant setting. Blood samples were collected pre-transplant before the start of and after conditioning therapy (1 day pre-transplant) and 2, 4, 6, 10, 20, 30 days following allo-HSCT. The analysis of potential risk factors included IL-2 and IFN-gamma concentrations, patients' age, the use of MAC/RIC and CR/non-CR status before transplantation. RESULTS: The statistical analysis revealed that independent risk factors for aGvHD included non-CR status before allo-HSCT [odds ratio (OR) = 10.52, P = 0.040], the use of MAC [hazard ratio (HR) = 4.80, P = 0.007] and a high level of IFN-gamma on day 6 post-transplant (HR = 1.03, P = 0.032). MAC was also the independent risk factor for infectious complications (OR = 4.04, P = 0.024). CONCLUSION: A high level of IFN-gamma on day 6 post-transplant, non-CR status before allo-HSCT and the use of MAC are independent risk factors for aGvHD. MAC is also the independent risk factor of infectious complications. AJBR
Authors: Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh Journal: Biol Blood Marrow Transplant Date: 2009-10 Impact factor: 5.742
Authors: Kathrin Rieger; Christoph Loddenkemper; Jochem Maul; Thomas Fietz; Daniel Wolff; Harald Terpe; Beate Steiner; Erika Berg; Stephan Miehlke; Martin Bornhäuser; Thomas Schneider; Martin Zeitz; Harald Stein; Eckhard Thiel; Rainer Duchmann; Lutz Uharek Journal: Blood Date: 2005-11-08 Impact factor: 22.113
Authors: Mary E D Flowers; Yoshihiro Inamoto; Paul A Carpenter; Stephanie J Lee; Hans-Peter Kiem; Effie W Petersdorf; Shalini E Pereira; Richard A Nash; Marco Mielcarek; Matthew L Fero; Edus H Warren; Jean E Sanders; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin Journal: Blood Date: 2011-01-24 Impact factor: 22.113
Authors: D Weisdorf; R Hakke; B Blazar; W Miller; P McGlave; N Ramsay; J Kersey; A Filipovich Journal: Transplantation Date: 1991-06 Impact factor: 4.939
Authors: Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti Journal: Blood Date: 2007-09-04 Impact factor: 22.113